Who
Dennis Mulroy
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Arcturus Therapeutics Holdings; Chief Financial Officer, AnaptysBio; Chief Financial Officer, La Jolla Pharmaceutical Co; Chief Financial Officer, Cardium Therapeutics.
In numbers
- Trades disclosed
- 143
- Buys
- 1
- Sells
- 11
- Bought
- $17K
- Sold
- $2.7M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 9 Mar 2009
- Last trade
- 1 May 2026
- Last filed
- 7 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 7 May 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $112K2,515 at $44.71 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $112K2,515 at $44.71 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —6,700 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —6,700 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —6,700 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —6,700 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $86K1,908 at $45.11 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $86K1,908 at $45.11 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —5,245 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —5,245 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —5,245 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —21,400 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —29,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —21,400 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —29,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —5,245 | filing |
| 5 Jan 2026filed 6 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $145K3,363 at $43.26 | filing |
| 5 Jan 2026filed 6 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $145K3,363 at $43.26 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Dennis Mulroy; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.